))
"Where Do We Go From Here?" Targeted Therapies Lead to Challenging Choices in Breast Cancer
Manage episode 442326055 series 3560609
Treść dostarczona przez Jacqueline Stone and Oncololgy News Central. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez Jacqueline Stone and Oncololgy News Central lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.
Newly approved targeted therapies for patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are changing care. “We have an abundance of opportunities, but challenges with having to choose the right opportunity at the right time,” says Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. Dr. Figlin discusses how to navigate new options with Manali Bhave, MD, a breast medical oncologist and assistant professor at the Emory University School of Medicine in Atlanta. Dr. Bhave stresses that disease progression in breast cancer can’t be addressed with a one-size-fits- all option. “Where do we go from here? I think it is largely dependent on clinical factors, patient comorbidities, and even biomarker status,” she explains. Dr. Bhave and Dr. Figlin discuss recent developments in targeted therapies and important challenges. “We’ve come a long way in treating metastatic HR-positive, HER2-negative breast cancer as more of a chronic disease,” she says.
Dr. Bhave reported consulting fees from Lilly, Novartis, and AstraZeneca.
Dr. Figlin reported various financial relationships.
124 odcinków
Udostępnij
